← Retour au Screener

Sector: Santé
Open in Terminal → NTRALive chart · Key metrics · News · Smart money

Natera

NTRA Large Cap

Healthcare · Diagnostics & Research

Mis à jour: Jun 18, 2026, 22:21 UTC

201,95 €
+2.19% aujourd'hui
52W: 115,03 € – 223,72 €
52W Low: 115,03 € Position: 80% 52W High: 223,72 €

Price Chart

Indicateurs clés

P/E Ratio
Cours/Bénéfice
Forward P/E
P/E prévisionnel
P/S Ratio
13.25x
Cours/Ventes
EV/EBITDA
Valeur d'entreprise/EBITDA
Rend. dividende
Rendement annuel du dividende
Cap. boursière
28,9 Md €
Capitalisation boursière
Croissance du CA
38.8%
Croissance du CA sur un an
Marge bénéficiaire
-9.05%
Marge nette
ROE
-15.02%
Rentabilité des capitaux propres
Beta
1.54
Sensibilité au marché
Positions vendeuses
2.6%
% du flottant vendu à découvert
Volume moyen
1,405,155
Volume quotidien moyen

Valuation Analysis

Signal
N/A
vs. S&P 500 avg P/E (24.7x)
Analyst Consensus
Acheter
20 analysts
Avg. Price Target
226,94 €
+12.38% upside
Target Range
168,43 € – 261,80 €

About the Company

Sector: Healthcare Industry: Diagnostics & Research Country: United States Employees: 6,135 Exchange: NMS

Natera en bref

Natera (NTRA) is currently trading at 201,95 € with a market capitalization of 28,9 Md €. The 52-week range spans from 115,03 € to 223,72 €; the current price is 9.7% below the yearly high. Year-over-year revenue growth stands at +38.8%.

💰 Dividende

Natera currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

20 analystes évaluent Natera (NTRA) au consensus : Acheter. L'objectif de cours moyen est de 226,94 €, soit un potentiel de +12.38% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 168,43 € à 261,80 €.

Natera : la thèse d'investissement en détail

Natera (NTRA) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 38.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 65.07%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.

Signal Smart Money

On the institutional side, Natera appears in the disclosed holdings of Druckenmiller. Smart-money managers track positioning, fundamentals and competitive dynamics with research budgets few retail investors can match — when several converge on the same name, it is rarely random. That doesn't mean blind copying makes sense, but it does raise the bar for the bear case.

Thèse d'investissement : forces et faiblesses

Points forts
  • Forte croissance du CA de 38.8% sur un an
  • Marge brute élevée de 65.07% — signe d'un pouvoir de fixation des prix
  • Consensus des analystes : Buy
  • Bilan solide avec faible endettement (D/E 13.53)
  • Free cash flow positif
Points faibles
  • Actuellement non rentable

Aperçu technique

MM 50 jours
181,05 €
+11.54% vs. cours
MM 200 jours
180,00 €
+12.19% vs. cours
Sous le plus haut 52s
−9.7%
223,72 €
Au-dessus du plus bas 52s
+75.6%
115,03 €

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

Risque de marché (Bêta)
1.54 · Élevé
Évolue plus que le marché global
Positions vendeuses
2.6% · Faible
% du flottant vendu à découvert
Dette/Capitaux propres
13.53 · Faible
Dette totale / capitaux propres

The data points to above-average price swings.

Trading Data

50-Day MA: 181,05 €
200-Day MA: 180,00 €
Volume: 2,272,370
Avg. Volume: 1,405,155
Short Ratio: 2.06
P/B Ratio: 18.62x
Debt/Equity: 13.53x
Free Cash Flow: 119 M €

More Santé stocks

Top peers in the same sector — ranked by market cap.

View full Santé sector page →

Where can I buy Natera?

Compare top-rated brokers — low fees, trusted providers, fully regulated.

Live Market Data

Real-time chart, financials, earnings, analysts, insider trades, events & news

Financials

Earnings

Analyst Ratings

Insider Trades

Events Timeline

News + Sentiment

Peer Comparison

Retour en haut